---
title: Mixed Connective Tissue Disease (MCTD)
url: "https://www.yyhmedical.com/en/guide/autoimmune/disease-mixed-connective-tissue-disease"
type: MedicalWebPage
inLanguage: en-US
---

# Mixed Connective Tissue Disease (MCTD)

> Mixed connective tissue disease (MCTD) is a rare systemic autoimmune disease characterized by overlapping features of conditions such as systemic lupus erythematosus, systemic sclerosis, inflammatory myositis, and rheumatoid arthritis, together with high levels of anti-U1-RNP antibodies.

## Overview

MCTD is an autoimmune disease with overlapping features of several connective tissue diseases. A patient may have Raynaud phenomenon and swollen fingers resembling systemic sclerosis, arthritis resembling rheumatoid arthritis, muscle inflammation resembling inflammatory myositis, and lupus-like manifestations.

  

Anti-U1-RNP antibodies are a key immunologic feature of MCTD, but antibody positivity alone is not enough to establish the diagnosis. Clinical findings must also be considered.

  

Symptoms can vary widely between patients and may change over time. Some people continue to have a typical MCTD pattern, while others may eventually develop features that more closely fit another defined connective tissue disease.

## Causes and Risk Factors

The exact cause of MCTD is not known.

  

Genetic susceptibility and abnormal immune responses are thought to contribute. Anti-U1-RNP antibodies and altered B-cell, T-cell, and immune-complex activity may play roles in vascular inflammation, arthritis, myositis, and lung involvement.

  

MCTD is not known to result from a single infection, lifestyle factor, or environmental exposure. It is more common in women but can occur at any age and in any sex.

## Signs and Symptoms

Symptoms usually do not appear all at once and may evolve over months or years.

  

Common manifestations include Raynaud phenomenon, swollen hands or fingers, joint pain or arthritis, muscle pain or weakness, fatigue, skin rashes, and symptoms related to esophageal dysfunction such as reflux or difficulty swallowing.

  

Some patients develop internal organ involvement. The most important pulmonary complications include interstitial lung disease and pulmonary arterial hypertension, which can cause dry cough, shortness of breath with activity, chest discomfort, or reduced exercise tolerance. Cardiac, renal, neurologic, and blood abnormalities may also occur.

## Diagnosis

No single test can diagnose MCTD on its own.

  

Diagnosis is based on the overall clinical pattern together with laboratory findings. Important tests may include ANA, anti-U1-RNP antibodies, complete blood count, complement and inflammatory markers, muscle enzymes, and kidney and urine testing.

  

Pulmonary function testing, high-resolution chest CT, and echocardiography may be used when lung or cardiovascular involvement is suspected.

  

There is currently no single internationally accepted diagnostic criteria set for MCTD. Several criteria systems are used as references, but diagnosis ultimately depends on the combination of high-titer anti-U1-RNP antibodies and compatible clinical manifestations.

## Treatment

There is no single treatment regimen for all patients with MCTD. Therapy is tailored to the symptoms and organs involved.

  

Joint pain and mild arthritis may be managed with nonsteroidal anti-inflammatory drugs, hydroxychloroquine, or other disease-modifying antirheumatic medications.

  

Raynaud phenomenon may improve with protection from cold, smoking avoidance, and medications such as calcium channel blockers when needed.

  

More significant inflammatory involvement, including myositis or pericarditis, may require corticosteroids together with immunomodulatory agents such as mycophenolate, methotrexate, azathioprine, or cyclophosphamide.

  

MCTD-associated interstitial lung disease should be managed jointly by rheumatology and pulmonary specialists. Treatment may include mycophenolate, rituximab, cyclophosphamide, or other therapies depending on severity and progression.

  

Pulmonary arterial hypertension requires specialist-directed therapy and may involve endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin-pathway therapies, or other pulmonary hypertension treatments.

## Content attribution (YMYL)
- Author:
- Medically reviewed by:
- Last reviewed:
- First published:

> 

---
Original (HTML):https://www.yyhmedical.com/en/guide/autoimmune/disease-mixed-connective-tissue-disease
This is a clean Markdown mirror for large language models; the original page is authoritative.